TLX•benzinga•
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Summary
Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 16, 2025 by benzinga